ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Interleukins"

  • Abstract Number: 1566 • ACR Convergence 2023

    Exposure-Response Analysis of Sarilumab in Patients with Polymyalgia Rheumatica

    Christine Xu1, Ying Liu1, Jennifer Sloane2, Remco Diab3, Hubert van Hoogstraten1, Hisham Abdallah4, Sreeraj Macha1 and Bhaskar Dasgupta5, 1Sanofi, Bridgewater, NJ, 2Sanofi, Cambridge, MA, 3Sanofi, Rotkreuz, Switzerland, 4Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 5Anglia Ruskin University, East Anglia, United Kingdom

    Background/Purpose: Sarilumab blocks interleukin-6 (IL-6) from binding to the membrane-bound and soluble IL-6 receptor-α subunit (IL-6Rα). Sarilumab is now approved for both rheumatoid arthritis (RA)…
  • Abstract Number: 2539 • ACR Convergence 2023

    Baseline IL-10 Levels as a Predictive Biomarker for Achieving Clinical Response with Abatacept in ACPA+ Patients with Early RA

    Jinqi Liu1, Yicong Li2, Kai Fu1, Chun Wu1, Peter Schafer3, Sean Connolly1, Ian M. Catlett4, Michael Maldonado1, Robert Wong5, Paul Emery6, Yoshiya Tanaka7, Vivian Bykerk8, Clifton Bingham9, Thomas Huizinga10 and Roy Fleischmann11, 1Bristol Myers Squibb, Princeton, NJ, 2Parexel International, Durham, NC, 3Bristol Myers Squibb, Belle Mead, NJ, 4Bristol Myers Squibb, Pennington, NJ, 5Bristol Myers Squibb (at the time of analysis), Princeton, NJ, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 7University of Occupational and Environmental Health, Kitakyushu, Japan, 8Department of Rheumatology, Hospital for Special Surgery, New York, NY, 9Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, 10Leiden University Medical Center, Leiden, Netherlands, 11Division of Rheumatology, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: A key target of RA treatment is to achieve early and sustained remission in order to ensure lower levels of long-term structural joint damage…
  • Abstract Number: 0012 • ACR Convergence 2023

    Immune-cell Derived Cytokines Synergistically Interact to Drive Synovial Fibroblast Invasive Function and Metabolic Capacity

    Órla Tynan1, Achilleas Floudas2, Nuno Neto3, Michael Monaghan3, Siobhán Wade4, Dumitru Anton5, Carl Orr6, Douglas Veale7 and Ursula Fearon8, 1Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, 2Dublin City University, Dublin, Ireland, 3Department of Mechanical and Manufacturing Engineering, Trinity College Dublin, Dublin, Ireland, 4Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, 5Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, 6EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, 7St.Vincent's University Hosp, Dublin, Ireland, 8Trinity College Dublin, Dublin, Ireland

    Background/Purpose: Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) encompass two of the most common forms of Inflammatory Arthritis. While common pathogenic mechanisms are involved in…
  • Abstract Number: 1571 • ACR Convergence 2023

    Tocilizumab in Pregnant Takayasu Arteritis – The Use of Tocilizumab at Conception and Throughout Pregnancy in Those with Takayasu Arteritis

    Nurul Aulia Zakaria1, Andrew Porter2, Robert Maughan2, Charis Pericleous2, Japna Satara3, Matthew Colquhoun4, Priyanka Agrawal3, jan Nouza3, Harold Wilson-Morkeh3, Taryn Youngstein2 and Justin Mason2, 1National Heart & Lung Institute, Imperial College London, Kuantan, Malaysia, 2National Heart & Lung Institute, Imperial College London, London, United Kingdom, 3Rheumatology, Hammersmith Hospital, London, United Kingdom, 4Department of Rheumatology, Imperial College Healthcare Trust, London, United Kingdom

    Background/Purpose: Takayasu arteritis (TA) is a large vessel vasculitis predominantly affecting female of reproductive age. Tocilizumab (TCZ) is frequently used in synthetic DMARD refractory cases.…
  • Abstract Number: 2548 • ACR Convergence 2023

    Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials

    Martin Rudwaleit1, Matthew A. Brown2, Floris Van Gaalen3, Nigil Haroon4, Lianne Gensler5, Carmen Fleurinck6, Alexander Marten7, Ute Massow8, Natasha De Peyrecave9, Thomas Vaux10, Katy White10, Atul Deodhar11 and Irene van der Horst-Bruinsma12, 1University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, 2Genomics England, London, United Kingdom, 3Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, 4University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Medicine/Rheumatology, Toronto, ON, Canada, 5University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, 6UCB Pharma, Oosterzele, Belgium, 7UCB Pharma, Monheim, Germany, 8UCB Pharma, Monheim am Rhein, Germany, 9UCB Pharma, Brussels, Belgium, 10UCB Pharma, Slough, United Kingdom, 11Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, 12Radboud University Medical Centre, Department of Rheumatology, Nijmegen, Netherlands

    Background/Purpose: Acute anterior uveitis ('uveitis'), or 'iritis', is a common extra-musculoskeletal manifestation among patients (pts) with axial spondyloarthritis (axSpA).1 IL-17 has been implicated in the…
  • Abstract Number: 0084 • ACR Convergence 2023

    Excess IL-18 Protects from Experimental Autoimmune Encephalomyelitis Mainly via Preferential Augmentation of Suppressor/Regulatory over Autoreactive T-cell Function

    Jeremy Morrissette1, Vinh Dang2, Jemy Varghese2, Zachary Lanzar1, Junior Nguyen2, Emily Landy3, Anastasia Frank-Kamenetskii4 and Scott Canna2, 1University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, 2Children's Hospital of Philadelphia, Philadelphia, PA, 3University of Pittsburgh, Pittsburgh, PA, 4CHOP/UPENN, Philadelphia, PA

    Background/Purpose: Interleukin 18 (IL-18) is an inflammasome-activated cytokine that canonically amplifies interferon-gamma (IFNg) production and cytotoxicity by CD8 T-cells (CD8Ts) and Th1 CD4 T-cells (CD4Ts).…
  • Abstract Number: 1601 • ACR Convergence 2023

    Interleukin-6 Disrupts Blood-cerebrospinal Fluid Barrier Permeability in Murine Neuropsychiatric Lupus

    Joshua Reynolds1, Lola Torz2, Natalia Petersen2, Ayal Ben-Zvi3 and Chaim Putterman1, 1Albert Einstein College of Medicine, Bronx, NY, 2Novo Nordic, Global Obesity Research, Malov, Denmark, 3Hebrew University of Jerusalem, Jerusalem, Israel

    Background/Purpose: In exploring the pathogenic mechanisms underlying neuropsychiatric lupus (NPSLE), it was discovered that cerebrospinal fluid (CSF) from lupus patients often contains neurotoxic antibodies, cytokines,…
  • Abstract Number: 2569 • ACR Convergence 2023

    Efficacy and Safety of Therapeutic Interventions for the Treatment of Still’s Disease: A Systematic Review and Meta-analysis Informing the EULAR/PReS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease

    Sara Bindoli1, Arianna De Matteis2, STEPHANE MITROVIC3, Bruno Fautrel4, Loreto Carmona5, Fabrizio De Benedetti6 and On Behalf Of The Eular/PreS QoC011 Task Force Member7, 1Rheumatology Unit, Dept of Medicine, University of Padova, Padova, Italy, 2IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, 3Pitie Salpetriere Hospital, Sorbonne University, APHP, Paris, France, 4Sorbonne Université APHP, Paris, France, 5Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, 6Bambino Gesu Children's Hospital, Division of Rheumatology, Rome, Italy, 7EULAR/PReS QoC011 Task Force members are: Jordi Anton, Alexandre Belot, Claudia Bracaglia, Tamas Constantin, Lorenzo Dagna, Alessandro De Bartolo, Eugen Feist, Dirk Foell, Marco Gattorno, Sophie Georgin-Lavialle, Roberto Giacomelli, Alexei Grom, Yvan Jamilloux, Katarina Laskari, Calin Lazar, Francesca Minoia, Peter Nigrovic, Filipa Oliveira Ramos, Seza Ozen, Pierre Quartier-dit-Maire, Piero Ruscitti, Erdal Sag, Sinisa Savic, Marie-Elise Truchetet, Bas Vastert, Tanita Wilhelmer, Carine Wouters., Paris, France

    Background/Purpose: To investigate the efficacy and safety of therapies currently in use and under evaluation for systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-Onset Still's disease…
  • Abstract Number: 0090 • ACR Convergence 2023

    Reduced Frequency of RORγt+ Regulatory T Cells Is Associated with Secukinumab Response in Axial Spondyloarthritis

    Addison Pacheco1, Michael Tang1, Sinead Maguire2, Melissa Lim1, Fataneh Tavasolian3, Zoya Qaiyum4 and Robert Inman1, 1University Health Network, Toronto, ON, Canada, 2Toronto Western Hospital, Toronto, ON, Canada, 3Krembil Research Institute, University Health Network, Toronto, ON, Canada, 4Krembil Research Institute, Toronto, ON, Canada

    Background/Purpose: Axial spondyloarthritis (AxSpA) is an inflammatory disease that predominantly affects the spine and the sacroiliac joints. Dysregulation of Type 3 immunity has been implicated…
  • Abstract Number: 1747 • ACR Convergence 2023

    A Newly Described Cytokine interleukin-40 Is Increased in the Serum of Individuals At-risk of Rheumatoid Arthritis and Induces an Inflammatory Response in Mononuclear Cells

    Adela Navratilova1, Klára Prajzlerová2, Nora Růžičková3, Karel Pavelka4, Jiri Vencovsky5, Ladislav Senolt6, Maria Filkova3 and Lucie Andrés Cerezo3, 1Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Hlavní město Praha, Czech Republic, 2Institute of Rheumatology, Prague, Czech Republic, 3Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 4Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, 5Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 6Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic

    Background/Purpose: Interleukin-40 (IL-40) is a newly described cytokine related to malignancies and immunity function. We have previously shown that IL-40 is up-regulated in early stages…
  • Abstract Number: 113 • 2023 Pediatric Rheumatology Symposium

    Proportion of Patients with a Polyphasic Disease Course in Systemic-onset Juvenile Idiopathic Arthritis May Be Higher in the Age of Cytokine Inhibitors

    Itay Marmor1, Rotem Semo Oz2, Amir hendel3, Guy Hazan4, Kevin Baszis5, Anthony French5, Cuoghi Edens6, Irit Tirosh7, Yonatan Butbul Aviel8, Liora Harel9 and Gil Amarilyo10, 1Dana-Dwek Children's Hospital, Hod Hasharon, Israel, 2Sheba medical center, Herzelyia, Israel, 3Tel Aviv University, Tel Aviv, Israel, 4Soroka University Medical Center, Be'er Sheva, Israel, 5Washington University School of Medicine, St Louis, MO, 6University of Chicago, Chicago, IL, 7Sheba Medical Center, Savyon, Israel, 8Rambam Medical center, Haifa, Israel, 9Scheiders Children Medical Center of Israel, Petah-Tiqva, Israel, 10Schneider Children's Medical Center of Israel, Petach Tikva, Israel

    Background/Purpose: Systemic-onset juvenile idiopathic arthritis (sJIA) is a pediatric autoinflammatory condition, known for significant variability between patients in its severity and long-term outcomes. The classification…
  • Abstract Number: 0580 • ACR Convergence 2022

    18F-FDG PET-MR Characterization of Aortitis in the IL1rn-/- Mouse Model of Giant-Cell Arteritis

    Samuel Deshayes1, Caroline Baugé2, Pierre-Antoine Dupont2, Christophe Simard2, Hubert De Boysson1, Alain Manrique2 and Achille Aouba1, 1Department of Internal Medicine, UR4650 PSIR, Normandie Univ, UNICAEN, CHU de Caen Normandie, Caen, France, 2UR4650 PSIR, Normandie Univ, UNICAEN, Caen, France

    Background/Purpose: Metabolic imaging is routinely used to demonstrate aortitis in patients with giant-cell arteritis. We aimed to investigate aortitis in BALB/c IL1rn-/- mice, a preclinical…
  • Abstract Number: 1547 • ACR Convergence 2022

    Effectiveness of Interleukin-6 Receptor Inhibitors for Polymyalgia Rheumatica

    Jeffrey Curtis1, Kerri Ford2, Stefano Fiore3, Danielle Isaman4, Lita Araujo5, Natalia Petruski-Ivleva6 and Fenglong Xie7, 1Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Sanofi, Destin, FL, 3Sanofi, Bridgewater, NJ, 4Sanofi, Chapel Hill, NC, 5Sanofi, Cambridge, MA, 6Sanofi, Unknown, 7University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Interleukin-6 receptor (IL-6R) inhibition has been shown to be effective in giant cell arteritis but data are limited in polymyalgia rheumatica (PMR). We conducted…
  • Abstract Number: 0581 • ACR Convergence 2022

    Mutants Improving Stability Enhance the Potency of Treg-Selective IL-2 Mutein for the Treatment of Autoimmune Disorders

    Yingying Hu1, Hu Ge1, Yuxi Yan1, Yun Zhang2, Xiaoxing Huang1, Zhenna Gao2, Yiming Kou2, Mi Ye2, Lei Zhou1, Siyuan Shao1, Bowei Yin1, Zhenzhen Li1, Yayuan Fu1, Wenqing Yang1, Zhuoxiao Cao1 and Renhong Tang1, 1Simcere Pharmaceutical Group, Shanghai, China, 2Simcere Pharmaceutical Group, Nanjing, China

    Background/Purpose: Low-dose IL-2 with enhanced sensitivity to Treg cells has been proved to be safe and efficacious in multiple autoimmune disorders (AIDs) including SLE, RA,…
  • Abstract Number: 1599 • ACR Convergence 2022

    Bimekizumab Treatment in Patients with Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors: 16-Week Efficacy and Safety from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

    Joseph Merola1, Robert Landewé2, Iain B McInnes3, Philip J Mease4, Christopher Ritchlin5, Yoshiya Tanaka6, Akihiko Asahina7, Frank Behrens8, Dafna Gladman9, Laure Gossec10, Richard Warren11, Barbara Ink12, Deepak Assudani12, Rajan Bajracharya12, Jason Coarse13 and Laura Coates14, 1Harvard Medical School, Brigham and Women's Hospital, Boston, MA, 2Amsterdam University Medical Center, Meerssen, Netherlands, 3Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 4Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 5Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, 6University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, 7Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, 8Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, 9Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 10Sorbonne Université, Paris, France, 11The University of Manchester, Manchester, United Kingdom, 12UCB Pharma, Slough, United Kingdom, 13UCB Pharma, Raleigh, NC, USA, Raleigh, NC, 14Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. The phase 3 BE COMPLETE study assessed the efficacy…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 11
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology